The study consists of an open-label AXS-14 treatment period followed by a randomised, double-blind treatment period.

AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor being developed for the management of fibromyalgia. Esreboxetine is the SS-enantiomer of racemic reboxetine.

A retired investigator for the state chiropractic board tells us this is the one case that he could not forget -- the one that got away, in his words. And he is frustrated that the board has been ...

Paul Whitcomb, a South Lake Tahoe chiropractor, believes he has found a cure for fibromyalgia, a disease that hypersensitizes the nervous system and causes debilitating pain in millions of Americans, ...

TNX-102 SL is a non-opioid, centrally-acting analgesic administered at bedtime for the treatment of fibromyalgia. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ...

A study conducted by British researchers found that patients with fibromyalgia (FM) reported improved quality of life following use of medical cannabis pro | Health And Medicine ...